Myomo

MYO · NYSE American

$1.26+$0.01 (+0.80%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $1.25

MYO analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $4.64 (+268.3% upside)

Low: $1.72
Now: $1.26
High: $11.02

Upgrades and downgrades

The latest rating actions, newest first

MYO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Ascendiant Capital	Aug 27, 2026	Maintains	Buy	$10.00 → $10.50	28%
Ascendiant Capital	Jun 8, 2026	Maintains	Buy	$9.50 → $10.00	28%
Ascendiant Capital	Nov 21, 2025	Maintains	Buy	$10.50 → $10.00	28%

The case for and against

Updated Oct 17, 2026

Bull case

Myomo is supported by accelerating commercialization, with fiscal Q2 2026 revenue of $11.7 million, up 21% year over year and above expectations, while EPS of $(0.09) also beat estimates. The business is gaining structural support from the March 2024 CMS ruling that expanded Medicare Part B reimbursement for MyoPro, helping drive 211 units sold in Q2 and a reimbursement pipeline of 1,491 alongside backlog of 218. Management’s raised 2026 revenue guidance to $45–47 million, plus strong U.S. O&P growth of 130% in Q2 and 32% international revenue growth, reinforces a positive outlook.

Bear case

Myomo is burdened by balance sheet and liquidity risk, with cash declining to $16 million from $18 million at the end of December while debt remained $11 million, leaving limited flexibility if commercialization or reimbursement progress stalls. Its outlook is further weakened by dependence on successful product adoption, maintaining regulatory approvals, and securing suitable insurance reimbursement, all of which are uncertain for a wearable medical robotics company that still faces commercialization execution risk. Competitive pressure, macroeconomic headwinds, and shifting investor, consumer, or government priorities for healthcare could further constrain demand and sentiment, making the stock fundamentally vulnerable despite its FDA-registered MyoPro device.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.